Remission in CML: Is DNA useful?

Blood

Volumn 116, Issue 8, 2010, Pages 1192-

  Mahon, François Xavier ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; IMATINIB; MESSENGER RNA;

ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; DNA SEQUENCE; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 77956522589     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-286310     Document Type: Note

References (7)

1. Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319-325.
2. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006;107(10):4171-4176. (Pubitemid 43726829)
3. Sobrinho-Simões M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 2010;116(8):1329-1335.
4. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program. 2009;477-487.
5. Branford S, Seymour JF, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13(23):7080-7085. (Pubitemid 350276891)
6. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood. 2007;109(1):58-60. (Pubitemid 46053043)
7. Mahon FX, Rea D, Guilhot F, et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 859.